Japan, Jan. 31 -- based Astellas Pharma Inc. has entered into a strategic collaboration with US-based Mass General Brigham that is focused on translational medicine and early development to establish an integrated approach to scientific advancement and clinical expertise.

Initial projects of mutual interest will be focused in key areas of R&D investment for Astellas, including oncology, rare disease, and cell and gene therapy. Through the alliance, Astellas and Mass General Brigham aim to accelerate innovation through collaborative research, as well as exploring and expanding new research frontiers; translate innovative research into clinical trials and actionable solutions that address serious unmet needs and aim to improve healthcare f...